clinical trial · NCT06657378
A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
Eisai Co., Ltd.·—·recruiting·n = 110
Partial-Onset SeizuresPrimary Generalized Tonic-clonic SeizuresNo Intervention
brief summary
The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures \[including secondarily generalized seizures\]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).
started
Nov 18, 2024
primary completion
Jun 15, 2028
completion
Jun 15, 2028
last updated
Jul 1, 2026
official title
A Multicenter, Postmarketing Observational (Noninterventional) Study to Evaluate the Safety of Fycompa for Injection in Patients With Partial-Onset Seizures (Including Secondarily Generalized Seizures) (Age 4 Years or Older) or Primary Generalized Tonic- Clonic Seizures (Age 12 Years or Older)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol